Deletions involving chromosome 10q23 occur frequently in prostatic carcinomas. Recently, a novel tumour suppressor gene, PTEN, mapping to this interval, has been identi®ed. Mutation or deletion of PTEN has been observed in a proportion of prostate cancer cell lines; however, primary prostate carcinomas have not been studied. We have investigated the involvement of PTEN in primary prostatic adenocarcinomas using a panel of 51 matched normal and prostate tumour DNAs. We ®rst determined the proportion of tumours with allele loss at loci in 10q23 which span the region containing the PTEN gene. Our results show that LOH involving 10q23 is common in primary prostate carcinomas. Twenty-®ve of 51 (49%) tumours showed loss of heterozygosity (LOH) over the region spanning the PTEN locus. We next directly analysed the PTEN gene for mutations of the coding region using single strand conformation polymorphism (SSCP) and sequence analyses. Of those tumours with LOH, only a single tumour was found to carry a missense mutation in PTEN. No mutations in PTEN were identi®ed in tumours without LOH. Our results suggest either that mutation of PTEN is a late event in prostate tumorigenesis, or that another tumour suppressor gene important in prostate cancer may lie close to PTEN in 10q23.
Introduction
Prostate cancer is the most common cancer in men, and the second leading cause of male cancer-related death in the Western world (Parker et al., 1996) . Despite the prevalence of the disease, little progress has been made in identifying genes important to its development. Loss of heterozygosity (LOH) studies have demonstrated that several chromosomal regions (most notably 7q, 8p, 10q, 16q and 17) are frequently lost in prostate tumours (Brothman, 1997; Cunningham et al., 1996) . Candidate tumour suppressor genes within these regions such as TP53 and Mxi1 have been implicated in a subset of advanced prostate carcinomas; however, no tumour suppressor gene has yet been demonstrated to have a major role in prostate tumorigenesis (Eagle et al., 1995; Gray et al., 1996; Lalani et al., 1997) .
Loci on both arms of chromosome 10 have been implicated in prostate carcinoma. LOH studies have suggested that at least one tumour suppressor on 10p (Trybus et al., 1996) and multiple distinct loci on 10q (Gray et al., 1996; Ittmann, 1996; Trybus et al., 1996) are involved in prostate cancer. Loss of loci from either arm appears to be correlated with advanced disease (Gray et al., 1996; Ittmann, 1996) . Of the frequently deleted regions of 10q in prostate carcinoma, the most common (*50% of tumours studied) spans 10q23 (Gray et al., 1996; Ittmann, 1996; Trybus et al., 1996) . Recently, a putative tumour suppressor gene has been isolated which maps to this interval. The gene, PTEN (phosphatase and tensin homologue deleted on chromosome ten) or MMAC1 (mutated in multiple advanced cancers 1), encodes a dual speci®city phosphatase Steck et al., 1997) .
PTEN has been implicated in a number of human tumour types. PTEN mutations have been observed in more than half of the glioblastoma cell lines and xenografted tumours examined, as well as in prostate carcinoma cell lines and, less frequently, in breast cancer cell lines Steck et al., 1997) . Mutations have also been identi®ed in primary glioblastoma, kidney and breast tumours, although at much lower frequencies than those observed in corresponding cell lines Steck et al., 1997) . The low incidence of PTEN mutations in primary tumours, as compared to cell lines, is somewhat surprising given the frequency of LOH at 10q23 in each of these primary tumour types (Albarosa et al., 1996; Kerangueven et al., 1996; Morita et al., 1991; Rasheed et al., 1995; Feilotter et al., submitted) . The lack of such mutations in these tumours could re¯ect the fact that PTEN inactivation is a very late event in tumorigenesis and thus, mutations are only observed in advanced stage tumours or cell lines. Alternatively, it is possible that PTEN does not represent the only or even the major tumour suppressor gene on 10q23, a possibility consistent with the ®nding of multiple distinct regions of allele loss on 10q in a variety of human tumours (Albarosa et al., 1996; Cappellen et al., 1997; Gray et al., 1996; Ittmann, 1996) .
The identi®cation of mutations and deletions of PTEN in four of six prostate tumour cell lines studied to date suggests a potential role for PTEN as a tumour suppressor in prostate carcinoma Steck et al., 1997) . However, as primary prostate tumours have not been investigated for mutations, the contribution of PTEN inactivation to the early process of prostate carcinoma development needs to be established. We have examined a panel of 51 primary prostate tumours for LOH of loci in 10q23 which¯ank the PTEN locus and for mutation of the PTEN gene itself. Our results show that, while loss of hetero-zygosity in this region is common in primary prostate tumours, mutations in the PTEN gene are relatively rare.
Results

LOH analysis
The PTEN locus has been mapped to the interval between the marker loci D10S579 and D10S541 in 10q23 . We initially looked for LOH spanning this interval in DNA samples from primary prostate carcinomas. We analysed a panel of 51 paired prostate tumour and normal DNAs using seven microsatellite markers which span the 10q23 region and¯ank the PTEN locus (Figure 1 ). Of the 51 tumours examined, 30 (59%) showed LOH for at least one marker within this region (Figure 1 ). Seven of these tumours (1 ± 7) showed allelic loss at all informative marker loci tested and thus, were not useful for determining the critical region of loss. In the remaining 23 tumours, LOH was detected at a subset of informative loci within the 10q23 region.
Two major regions of allele loss were seen. The ®rst deleted region was de®ned by tumours 18 and 19. The shortest region of overlap (SRO1) lay between markers D10S1765 and D10S1735 (Figure 1 ). The second distinct SRO (SRO2) was de®ned by tumour 24 and lay between markers D10S219 and D10S1765 ( Figure  1) . A large number of the tumours had patterns of LOH consistent with loss spanning either SRO1 or SRO2, or both. These included tumour samples 8 ± 17, 20 ± 23 and 26 (Figure 1 ). Both SRO1 and SRO2 overlap the interval D10S541-D10S579 which spans the PTEN locus. It is also possible that homozygous deletions spanning the PTEN gene occurred in these tumours. As our analyses were performed on archival material using PCR-based methods it was not possible for us to address this question in these tumours.
A third, less common, region of loss was de®ned by tumours 27, 28 and 29, which showed loss at D10S573 but not at the more distal marker D10S219 (Figure 1 ). The centromeric limit of this region could not be determined as LOH extended beyond the most centromeric microsatellite marker used in this study. Tumours 25, 26 and 30 also showed patterns of loss that included this region, although these patterns could also be interpreted as showing loss within SRO2 (Figure 1 ).
In summary, multiple discrete regions of allele loss were identi®ed in the panel of prostate tumours examined. The two regions most commonly deleted, SRO1 and SRO2 (Figure 1 ), lie within the interval that also encompasses the PTEN locus. The third region is centromeric to the other two (Figure 1) , and also to the PTEN interval.
SSCP analysis
We next looked for mutations in the PTEN coding region in our prostate tumour samples using single strand conformation polymorphism (SSCP) analysis. For each tumour sample and control, PTEN exons were ampli®ed using intronic primers. PCR products with altered mobility, suggesting the presence of mutations, were directly sequenced. Using the data from the LOH analysis, our panel could be divided into two groups: those with LOH within or spanning the PTEN interval and those with no detectable LOH in that region. The ®rst group included all tumours with LOH at either SRO1 or SRO2 (25 tumour samples) (Figure 1 ). The second group included all tumours with loss exclusively centromeric of D10S579 and all tumours where no loss was detected for any microsatellite marker used (26 tumour samples). As a control, we also used 60 DNAs obtained from a blood donor population.
We performed SSCP analysis for each PTEN exon ( Figure 2 ) on all samples in each of the three groups. At least two gel conditions were tested for each sample for each exon to maximize the chance of identifying SSCP variants corresponding to PTEN mutations. No SSCP variants were seen for exons 1, 3, 5, 7, 8 or 9 for any tested sample.
Multiple distinct banding patterns were observed in SSCP analyses of exons 2 and 4 from each of the three groups of tumours tested, suggesting the presence of a polymorphism. In addition, a single SSCP variant was seen in exon 6 for tumour sample 19. This sample belonged to the group with LOH spanning the PTEN locus ( Figure 1 ) and was not distinguishable from the others by any available clinical criteria (Figure 1 ). The same SSCP variant was not seen in DNAs from either the tumours with no LOH over the PTEN locus, or in the blood controls.
PTEN polymorphisms
For exons 2 and 4, sequencing was performed on samples representing each SSCP pattern. For exon two, three distinct SSCP patterns were seen, corresponding to two alleles, with frequencies of approximately 0.44 and 0.56. Sequencing of exon 2 revealed an A to G base substitution in intron 1, 98 base pairs upstream of the start of exon 2 (IVS1-98A/G). For exon 4, three distinct SSCP patterns were seen as well, corresponding to two alleles with frequencies of 0.42 and 0.58. The polymorphism detected in PCR ampli®cation of exon 4 was a 5 base pair deletion (ATCTT) in intron 4, 108 base pairs downstream of exon 4. The relative frequencies of the alleles for each polymorphism was roughly equal within each of the three groups of samples tested.
PTEN mutations
A single base pair substitution (520T4A) was identi®ed in exon 6 from tumour sample 19. This change would result in the substitution of an asparagine for a tyrosine at amino acid 174 (Y174N). This change was not present in the matched constitutional DNA sample from patient 19. We con®rmed the presence of the 520T4A mutation using a restriction digest of ampli®ed PCR product. The presence of the base pair change would result in destruction of a HaeII restriction site present in the normal sequence. As shown in Figure 3 , the HaeII site was absent in the tumour DNA, but present in the normal DNA in patient 19.
Discussion
PTEN is a candidate tumour suppressor involved in a variety of human cancers, including prostate carcinoma Steck et al., 1997) . It encodes a dual speci®city phosphatase, with additional homology to the cytoplasmic proteins tensin and auxillin. The demonstrated phosphatase activity of PTEN (Li and Sun, 1997; Myers et al., 1997) suggests a role for the protein in both tyrosine and serine/threonine phosphate-mediated signal transduction. Mutation studies of PTEN have indicated that it may be involved in a variety of human tumours, including glioblastomas and prostate and breast carcinomas; however, this role is largely predicted from the study of cell lines Steck et al., 1997) .
The involvement of PTEN in prostate tumorigenesis has been predicted on the basis of PTEN mutations detected in a limited number of prostate carcinoma cell lines. Of six cell lines tested in two studies, only one (LNCaP) had a mutation in PTEN, and loss of the wild-type copy of the gene Steck et al., 1997) . Two others (PC-3 and NCI H660) had homozygous deletions spanning PTEN; however, these deletions extended telomeric of the gene for an undetermined distance, and likely also span other genes (Li et al., 1997) . One cell line (DU145) had an amino acid substitution in PTEN; however, in this case, there was retention of the wild-type copy of the gene . The remaining two cell lines (A10 and A11) had no detectable PTEN mutations (Steck et al., 1997) . Thus, from the cell line data, it is not clear whether PTEN is likely to have a major role in prostate tumorigenesis. In this study, we asked whether PTEN is mutated in primary prostate carcinomas using a panel of 51 tumour and paired normal DNAs from an unselected series of prostatectomies. We found ®rst, that LOH over the 10q23 region, including the PTEN locus, was very common in these tumours, occurring in about 50% of the cases, and second, that mutations in PTEN in the same set of tumours were very rare, occurring in only one sample. Our analyses, however, might not have detected homozygous deletions, or intronic or regulatory region mutations of PTEN. Expression studies to address the latter point were not possible with the archival material used here; however, mutation analyses of PTEN in cell lines have suggested that most mutations identi®ed to date occur within the coding regions of the gene Steck et al., 1997) .
Overall, our data suggest that loss of PTEN activity is not a frequent initiating event in prostate tumorigenesis. The cell lines studied previously were derived from metastatic disease (American Type Culture Collection, Rockville, MD), whereas the samples used in this study were exclusively from locally con®ned tumours (data not shown). Therefore, it is possible that mutation or deletion of PTEN is an event associated with advanced or metastatic disease. Although our sample size was small we saw no correlation of LOH in the 10q23 interval with more advanced disease stage or tumour grade. The high incidence of LOH over the PTEN region in our samples could re¯ect loss of one copy of PTEN without mutation of the other copy, however, it is dicult to explain the clonal selection of cells carrying one normal copy of the gene if PTEN is a classical tumour suppressor.
An alternative hypothesis is that the PTEN gene is not the major tumour suppressor at 10q23 involved in prostate cancer development. PTEN has been mapped to an interval spanned by the microsatellite markers D10S541 and D10S579 , a physical distance estimated at about 1 Mb (Chumakov et al., 1995) . It is likely that one or more additional genes maps within an interval of this size. SRO1 reported in this study lies between microsatellite markers D10S1735 and D10S1765, and SRO2 lies more proximally between D10S1765 and D10S219. D10S1765 lies between D10S541 and D10S579 (Gray et al., 1997; data not shown), and lies close to and centromeric of PTEN (Gray et al., 1997) . It is not clear whether one or both SROs from our study spans the PTEN gene and related regulatory regions. Other studies of LOH from prostate tumours have also detected a major region of loss at markers mapping near PTEN, between D10S541 and D10S215 (Gray et al., 1996) and between D10S215 and D10S219 (Trybus et al., 1996) . However, although all of these studies, and ours, predict the presence of at least one prostate tumour suppressor gene in a narrow interval of 10q23 containing these microsatellite markers, it is not yet clear whether these intervals are consistent with loss of PTEN.
This study also predicts the existence of at least one additional tumour suppressor gene with a role in prostate cancer mapping to 10q outside of the PTEN interval. These data are consistent with other LOH studies of prostate tumours, which have found multiple distinct regions of allele loss on 10q (Gray et al., 1996; Ittmann, 1996; Trybus et al., 1996) . In addition, numerous studies of other human tumour types have suggested multiple tumour suppressor loci may be found on 10q. The predicted regions include 10q24-qter in glioblastoma multiforme (Albarosa et al., 1996; Rasheed et al., 1995) , 10q23-q26 in endometrial cancer (Peier et al., 1995) , 10q21-q23 in renal cell carcinoma (Morita et al., 1991) , 10q22-qter in malignant melanoma (Herbst et al., 1994) , 10qter in hepatocellular carcinoma (Fujimori et al., 1991) and 10q24.1-q24.3 and 10q26.1-q26.2 in muscle-invasive bladder cancers (Cappellen et al., 1997) . Each of these regions crosses the predicted SROs described in this study. Whether the multiple regions represent events at one or more potential tumour suppressor loci is not clear, as the use of dierent microsatellite markers makes direct comparison across studies dicult.
In summary, we have shown that, although LOH on 10q23 is common in primary prostate carcinoma, mutations in a candidate tumour suppressor gene, PTEN, are not. It remains to be determined whether PTEN mutations contribute to prostate tumorigenesis, and if so, at what stage.
Materials and methods
Samples
Samples used in this study were a series of 51 primary prostatic adenocarcinomas from radical prostatectomies and matched constitutional tissues from seminal vesicles, lymph nodes or prostate. For all cases, regional lymph nodes were sampled and showed no metastases. The combined Gleason scores (GS) and tumour pathological stage (pT) for the carcinomas are available. Samples collected at the Kingston General Hospital between 1993 ± 1994 were obtained as formalin-®xed paran embedded archival material. After examination of a hematoxylin-phloxine-aron-stained section, tumour tissues were microdissected from contaminating normal cells and the DNA extracted according to published protocols (Wright and Manos, 1990; Feilotter et al., submitted) . Control blood DNAs from a panel of 60 unrelated individuals were extracted using established protocols (Mathew et al., 1987) .
LOH analysis of 10q23
Seven microsatellite markers that map to the 10q23 region were used for LOH analyses. The order of the markers (CEN D10S573, D10S219, D10S579, D10S1765, D10S541, D10S1735, D10S1739 TEL) was determined from published sources (Chumakov et al., 1995; Gyapay et al., 1994; Marsh et al., 1997; Moschonas et al., 1996; Nelen et al., 1996; Gray et al., 1997) and data from the Center for Genomic Research at the Whitehead Institute for Biomedical Science (www-genome.wi.mit.edu) or by PCR ampli®cation of PTEN-containing YACs (data not shown). Primer sequences for the microsatellites were obtained from the Genome Data Base.
PCRs for LOH analysis were performed in 20 ml volumes, and contained 100 ng genomic DNA, 200 mM each of dATP, dCTP, dTTP, dGTP (Pharmacia, Baie d'UrfeÂ , Canada), 2 mM forward and reverse primers, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.35 U Taq polymerase (Life Technologies, Inc., Burlington, Canada) and g 32 P-ATP endlabeled forward or reverse primer. Cycling conditions were 958C for 1 min, 558C for 30 s, 728C for 30 s repeated 30 times, followed by a 10 min extension at 728C. Aliquots of each reaction were electrophoresed on denaturing polyacrylamide gels at constant voltage. DNAs were analysed with each marker multiple times. Gels were dried and exposed to ®lm, and allelic loss was scored by eye by two independent observers. SSCP analysis of PTEN SSCP analysis was carried out for each of the nine exons of the PTEN gene. PCRs were performed in 20 ml volumes containing 100 ng genomic DNA, 200 mM each of dATP, dCTP, dTTP and dGTP, 2 mM forward and reverse primers, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 0.4 uCi [a 32 P]dCTP, and 0.35 U Taq polymerase. Cycling conditions were 958C for 1 min, 548C for 1 min and 728C for 1 min, repeated 40 times. Aliquots of the labeled PCR products were electrophoresed on non-denaturing acrylamide/glycerol gels at 148C for 16 h using a variety of polyacrylamide and glycerol concentrations, ranging from 6 ± 8% acrylamide and 0 ± 10% glycerol. Gels were dried and exposed to ®lm. Sequence analysis of PTEN Two rounds of PCR were performed prior to sequencing. The ®rst used 100 ng of genomic DNA, and the second used puri®ed product from the ®rst PCR as template. Reaction conditions were as described above except that reaction volumes were increased to 60 ml and no isotope was added. PCR products were either puri®ed from low melt agarose gels using the Wizard PCR Preps DNA Puri®cation System (Promega, Madison, WI) or were pur®ed directly using the High Pure PCR Product Puri®cation Kit (Boehringer Mannheim, Laval, Canada). Products were sequenced using the Delta Taq Cycle Sequencing Kit (Amersham Life Sciences, Arlington Heights, IL) and either [a 32 P]dCTP or [a 35 S]dATP. Sequencing reactions were electrophoresed on denaturing polyacrylamide gels. The gels were dried and exposed to ®lm. Where possible, sequence variants were con®rmed by restriction digestion of ampli®ed PCR products according to manufacturer's speci®cations (Life Technologies, Inc., Burlington, Canada).
